Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP

Cephalalgia

Volumn 34, Issue 12, 2014, Pages 968-976

  Bigal, Marcelo E ^a   Walter, Sarah ^a   Bronson, Michele ^a   Alibhoy, Abbas ^a   Escandon, Rafael ^a  

^a TEVA PHARMACEUTICALS   (Israel)

Author keywords

cardiovascular; CGRP; monoclonal antibodies

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; LBR 101; MONOCLONAL ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; CALCITONIN GENE RELATED PEPTIDE;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; CARDIAC TELEMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG HALF LIFE; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMAN; MAXIMUM PLASMA CONCENTRATION; PR INTERVAL; QRS COMPLEX; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; SYSTOLIC BLOOD PRESSURE; TELEMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BLOOD PRESSURE; CALCITONIN GENE-RELATED PEPTIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART RATE; HUMANS; MIDDLE AGED;

EID: 84908158935     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102414527646     Document Type: Article

References (38)

1. Edvinsson L, Goadsby PJ. Extracerebral manifestations in migraine. A peptidergic involvement?. J Intern Med. 1990; 228: 299-304
2. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990; 28: 183-187
3. Hansen JM, Hauge AW, Olesen J, et al. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010; 30: 1179-1186
4. Ashina M, Bendtsen L, Jensen R, et al. Plasma levels of calcitonin gene-related peptide in chronic tension-type headache. Neurology. 2000; 55: 1335-1340
5. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010; 6: 573-582
6. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004; 350: 1104-1110
7. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372: 2115-2123
8. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011; 31: 712-722
9. Allen DM, Chen LE, Seaber AV, et al. Calcitonin gene-related peptide and reperfusion injury. J Orthop Res. 1997; 15: 243-248
10. Källner G, Gonon A, Franco-Cereceda A. Calcitonin gene-related peptide in myocardial ischaemia and reperfusion in the pig. Cardiovasc Res. 1998; 38: 493-499
11. Lynch JJ, Detwiler TJ, Kane SA, et al. Effect of calcitonin gene-related peptide receptor antagonism on the systemic blood pressure responses to mechanistically diverse vasomodulators in conscious rats. J Cardiovasc Pharmacol. 2010; 56: 518-525
12. Supowit SC, Ethridge RT, Zhao H, et al. Calcitonin gene-related peptide and substance P contribute to reduced blood pressure in sympathectomized rats. Am J Physiol Heart Circ Physiol. 2005; 289: H1169-H1175
13. Chan KY, Edvinsson L, Eftekhari S, et al. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther. 2010; 334: 746-752
14. Lynch JJ, Shen YT, Pittman TJ, et al. Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs. Eur J Pharmacol. 2009; 623: 96-102
15. Petersen KA, Birk S, Lassen LH, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005; 25: 139-147
16. Van der Schueren BJ, Blanchard R, Murphy MG, et al. The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men. Br J Clin Pharmacol. 2011; 71: 708-717
17. Chaitman BR, Ho AP, Behm MO, et al. A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina. Clin Pharmacol Ther. 2012; 91: 459-466
18. Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache. 2013; 53: 1230-1244
19. Bigal ME, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia.:
20. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Available at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129357.pdf. (2005, accessed December 2013).
21. Lundberg JM, Franco-Cereceda A, Hua X, et al. Co-existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin. Eur J Pharmacol. 1985; 108: 315-319
22. Goadsby PJ. Calcitonin gene-related peptide receptor antagonists and triptans: A tale of two treatments. Neurology. 2010; 75: 1494-1495
23. Silberstein SD. Emerging target-based paradigms to prevent and treat migraine. Clin Pharmacol Ther. 2013; 93: 78-85
24. Hoffmann J, Goadsby PJ. New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS inhibitors. Curr Treat Options Neurol. 2012; 14: 50-59
25. Salvatore CA, Moore EL, Calamari A, et al. Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther. 2010; 333: 152-160
26. Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014; 34: 114-125
27. Verheggen R, Bumann K, Kaumann AJ. BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: Comparison with CGRP(8-37). Br J Pharmacol. 2002; 136: 120-126
28. Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev. 2004; 84: 903-934
29. Brain SD, Williams TJ, Tippins JR, et al. Calcitonin gene-related peptide is a potent vasodilator. Nature. 1985; 313: 54-56
30. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988; 23: 193-196
31. Zhang JF, Liu J, Liu XZ, et al. The effect of calcitonin gene-related peptide on ischemic reperfusion-induced arrhythmias in rats. Int J Cardiol. 1994; 46: 33-36
32. Atkins BZ, Silvestry SC, Samy RN, et al. Calcitonin gene-related peptide enhances the recovery of contractile function in stunned myocardium. J Thorac Cardiovasc Surg. 2000; 119: 1246-1254
33. Zhou ZH, Peng J, Ye F, et al. Delayed cardioprotection induced by nitroglycerin is mediated by alpha-calcitonin gene-related peptide. Naunyn Schmiedebergs Arch Pharmacol. 2002; 365: 253-259
34. Walter S, Bronson M, Escandon R, et al. Cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against CGRP. American Academy of Neurology.:
35. Rodriguez I, Erdman A, Padhi D, et al. Electrocardiographic assessment for therapeutic proteins-scientific discussion. Am Heart J. 2010; 160: 627-634
36. Conolan S, Taylor DA. Antagonism by some ergot derivatives of 5-HT-induced vasoconstriction. Eur J Pharmacol. 1986; 123: 299-302
37. Maassen VanDenBrink A, Bax WA, Ferrari MD, et al. Augmented contraction of the human isolated coronary artery by sumatriptan: A possible role for endogenous thromboxane. Br J Pharmacol. 1996; 119: 855-862
38. Longmore J, Hargreaves RJ, Boulanger CM, et al. Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: Outcome of two independent studies using different experimental protocols. Funct Neurol. 1997; 12: 3-9